NVS Novartis AG
- 103.130
- +2.430+2.41%
- 103.000
- -0.130-0.13%
Novartis AG News
Express News | NYSE Order Imbalance 68931.0 Shares on Sell Side
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis Boasts Scemblix Beats Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Novartis Reports Positive Phase 3 Data for Remibrutinib for Chronic Hives
Express News | Novartis Pharmaceuticals CEO Vas Narasimhan said that even though the company has no diet pills, the business is on a good track.
Express News | Novartis CEO: Even without diet pills, the company has maintained a good momentum of development.
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints
Novartis (NVS) said Friday that the late-stage trial for its treatment for chronic myeloid leukemia, Scemblix, has met both of its primary endpoints. Scemblix demonstrated clinically significant effic
Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-
Arvinas - Novartis Pharmaceuticals AG will pay the company US$150 million due to the termination of Hsr and meeting the transaction conditions of the license agreement and asset agreement
Arvinas - Novartis Pharmaceuticals AG will pay the company US$150 million due to the termination of Hsr and meeting the transaction conditions of the license agreement and asset agreement
AstraZeneca, Novo Nordisk, Novartis Show Innovation Momentum -- Market Talk
1551 GMT - AstraZeneca, Novo Nordisk and Novartis are charting strong innovation narrative that should boost near and mid-term earnings momentum, Goldman Sachs analysts say in a note. AstraZeneca's in
Goldman Sachs pushes European pharmaceutical stocks: innovation leads the future, and the three giants receive buying ratings
The European pharmaceutical company focused on developing new drug combinations was recognized by Goldman Sachs Group analysts.
Novartis Started at Buy by Goldman Sachs
Novartis Started at Buy by Goldman Sachs
Novartis Target Started at CHF109 by Goldman Sachs
Novartis Target Started at CHF109 by Goldman Sachs
European pharmaceutical giant praised by Goldman Sachs: innovation is king, and three shares received a “buy” rating
European pharmaceutical companies focused on building new drug combinations were recognized by Goldman Sachs analysts.
Express News | Goldman Sachs gave Novartis the initial rating for the purchase, with a target price of CHF 109.
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com
By Josh Nathan-Kazis What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger selloff Wednesday. The stock was down 5.5% Wednesday morning, bringing the stocks
AstraZeneca Touts PCSK9 Inhibitor in Lowering LDL Cholesterol When Added to Statin
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Novartis Reports Phase 3 Results for IgA Nephropathy Treatment
Reported Saturday, Novartis' Latest Phase III Data For Fabhalta (Iptacopan) In C3 Glomerulopathy (C3G) A Significant 35.1% Reduction In Proteinuria Compared To Placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical
Analysis
Price Target
No Data
